The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics
- 1.2k Downloads
While therapeutic proteins (TP), particularly recombinant human proteins and fully human monoclonal antibodies, are designed to have a low immunogenic potential in humans, a clinical immune response does sometimes occur and cannot be predicted from preclinical studies. Changes in TP pharmacokinetics may be perceived as an early indication of antibody formation and serve as a surrogate for later changes in efficacy and safety in individual subjects. Given the substantial increase in number of biological products, including biosimilars, there is an urgent need to quantitatively predict and quantify the immune response and any consequential changes in TP pharmacokinetics. The purpose of this communication is to review the utility of population-based modeling and simulation approaches developed to date for investigating the development of an immune response and assessing its impact on TP pharmacokinetics. Two examples of empirical modeling approaches for pharmacokinetic assessment are presented. The first example presents methods to analyze pharmacokinetic data in the presence of anti-drug antibody (ADA) and confirm the effect of immunogenicity on TP pharmacokinetics in early phases of drug development. The second example provides a framework to analyze pharmacokinetic data in the absence or with very low incidence of ADA and confirm with enough power the lack of an immunogenicity effect on TP pharmacokinetics in late phases of drug development. Finally, a theoretical mechanism-based modeling framework is presented to mathematically relate the complex interaction among TP, their targets, and ADA.
Key wordsimmunogenicity modeling and simulation pharmacokinetics therapeutic proteins
The authors thank Naren Chirmule, Bernd Meibohm, and Beverly Adler for the comments provided during the preparation of this manuscript. In addition, we also would like to thank Alin Chen, Sarah Hoofring, Adimoolam Narayanan, Marta Starcevic, Liviawati Sutjandra, and Thuy Vu for generating data and providing support and comments during the completion of this review. This study has been sponsored by Amgen Inc. Andrew T. Chow, Peiming Ma, and Juan Jose Perez Ruixo are employees and own stocks in Amgen Inc. They have no other conflict of interest to declare.
- 3.Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20 Suppl 6:3–9.Google Scholar
- 6.Kokate CK, Jalalpure SS, Hurakadle PJ. Textbook of pharmaceutical biotechnology. New Delhi: Elsevier; 2011. p. 22–23.Google Scholar
- 7.Gell PGH, Coombs RRA, editors. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.Google Scholar
- 12.FDA. FDA guidance for industry: population pharmacokinetics. 1999. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf. Accessed 2 Nov 2012.
- 13.CHMP. CHMP guideline on reporting the result of population pharmacokinetic analyses. Doc. Ref. EMEA/CHMP/EWP/185990/06. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf. Accessed 2 Nov 2012.
- 19.Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–59.Google Scholar
- 29.CHMP. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc. Ref. EMEA/CHMP/BMWP/14327/2006. 2007. http://www.tga.gov.au/pdf/euguide/bmwp1432706en.pdf. Accessed 2 Nov 2012.
- 32.Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64.PubMedCrossRefGoogle Scholar
- 36.Perez-Ruixo JJ, Doshi S, Chow AT. Application of pharmacokinetic–pharmacodynamic modeling and simulation for erythropoietic stimulating agents. In: Kimko HHC, Peck CC, editors. Clinical trial simulations. Applications and trends. New York: Springer; 2010. p. 311–28.Google Scholar